The hepatitis C medication boceprevir may have harmful interactions with calcium channel blockers and α1-adrenoreceptor antagonists, according to changes to the drug’s label recently approved by the US Food and Drug Administration (FDA).
The FDA approved boceprevir, a protease inhibitor, for the treatment of hepatitis C in May 2011. In April 2012, the agency issued a warning to not prescribe boceprevir in combination with ritonavir-boosted HIV protease inhibitors for individuals coinfected with hepatitis C and HIV because the combination can reduce the effectiveness of the drugs in combating both diseases.
Kuehn BM. Boceprevir Contraindications. JAMA. 2014;311(8):791. doi:10.1001/jama.2014.1337
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: